Whether these have any prognostic and therapeutic implications, such as careful selection of patients with specific phenotypes of COPD with elevated TNF-α and IL-1β levels who may benefit from individualized anti-TNF-α and anti-IL-1β treatment, is unclear at present and needs further studies. Here, IL1B is linked to chronic obstructive pulmonary disease.